🧬 PCOS Metabolic Syndrome Risk Calculator

Baseline Anthropometric & Lipid Assessment

PCOS raises lifelong cardiometabolic risk beyond reproductive symptoms alone.

• ~10%: PCOS prevalence (of reproductive-age women)
• ~43%: Metabolic synd. in PCOS (vs ~24% in controls)
• 88 cm: Central obesity threshold (waist, per ATP III women)
• 50–70%: Insulin resistance rate (across PCOS phenotypes)

Why anthropometrics anchor the model

BMI and waist circumference proxy visceral fat burden cheaply.

Lipid panel inputs

Triglycerides and HDL cholesterol flag early dyslipidemia patterns.

Why PCOS changes the baseline

Androgen excess independently worsens fat distribution and lipids.

Waist circumference predicts risk better than BMI alone in PCOS.

Hyperinsulinemia & Insulin Resistance

Compensatory hyperinsulinemia is the metabolic engine behind PCOS risk.

• 50–70%: Insulin resistance in PCOS (lean and obese phenotypes)
• >2.5: HOMA-IR elevated cutoff (common research threshold)
• ↑↑: Hepatic lipogenesis boost (driven by hyperinsulinemia)
• ~10–15: Beta-cell compensation years (before overt dysglycemia)

Insulin and the ovary-liver axis

Excess insulin amplifies ovarian androgen output and hepatic fat synthesis.

Pancreatic beta-cell strain

Beta cells overproduce insulin for years before failure appears.

Downstream cascade

Insulin resistance seeds both dyslipidemia and hepatic fat.

Insulin resistance is the common root of three later risks.

Atherogenic Dyslipidemia Risk

PCOS produces a distinct high-triglyceride, low-HDL lipid signature.

• ~30–40%: Elevated triglycerides (of PCOS patients)
• ~30%: Low HDL prevalence (below protective threshold)
• Small, dense: LDL particle shift (more atherogenic subtype)
• Early: Dyslipidemia onset (often before age 30)

The PCOS lipid signature

High triglycerides pair with stubbornly low HDL cholesterol.

Vascular consequence

Small dense LDL particles infiltrate arterial walls more readily.

Waist as the driver

Visceral fat directly fuels triglyceride overproduction in the liver.

Waist circumference tracks dyslipidemia tighter than BMI does.

Non-Alcoholic Fatty Liver Disease Risk

Hepatic fat quietly accumulates as insulin resistance persists untreated.

• ~35–70%: NAFLD prevalence in PCOS (vs ~20–30% general pop.)
• Yes: Independent of BMI (lean PCOS still at risk)
• ~20%: Progression to NASH (of NAFLD cases)
• Early: Reversibility window (with weight and insulin control)

How fat accumulates in the liver

Excess insulin pushes the liver to store fat instead of exporting it.

Why PCOS liver risk is distinct

Androgen excess compounds insulin-driven hepatic lipid accumulation.

Screening implication

Liver enzymes and imaging are underused in PCOS follow-up.

NAFLD risk rises steeply once BMI crosses the obese range.

Cumulative Type 2 Diabetes & Cardiometabolic Risk

All prior risk streams converge into one composite score.

• 4–8×: T2D risk in PCOS (higher than age-matched peers)
• ~30–40%: Prediabetes prevalence (by reproductive age)
• ~2×: Cardiovascular event risk (elevated lifetime risk)
• 0–100: Composite score range (this simulator's scale)

Combining the risk streams

Insulin resistance, dyslipidemia, and NAFLD sum into one gauge.

Why early calculation matters

Earlier detection allows lifestyle intervention before disease onset.

Using the composite score

Higher scores flag candidates for closer metabolic monitoring.

The composite score is illustrative, not a diagnostic instrument.